TYAN
2.6.2021 17:02:07 CEST | Business Wire | Press release
TYAN® , an industry-leading server platform design manufacturer and a MiTAC Computing Technology Corporation subsidiary, brings a variety of AI, cloud and storage server platforms incorporating the latest AMD EPYC™ 7003 Series processors in TYAN’s 2021 Server Solutions Online Exhibition beginning June 2nd .
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210602005045/en/
“As the continued growth of using clouds for running HPC workloads, modern data center operators need to raise the bar for improved business outcomes,” said Danny Hsu, Vice President of MiTAC Computing Technology Corporation's Server Infrastructure Business Unit. “With leadership performance and modern security features, TYAN’s 3rd Generation AMD EPYC processor-based platforms empower our customers to drive performance at a competitive price.”
Transport HX products deliver leadership compute in supercomputing and deep learning
Attendees will experience demonstrations on the latest AMD products and technologies in HPC, cloud, storage, and 5G halls at the 3D virtual environment. Leveraging 3rd Generation AMD EPYC processors, the Transport HX TN83-B8251 is a 2U dual-socket server with 16 DDR4-3200 DIMM slots, two half-height, half-length PCIe 4.0 x16 expansion slots for high-speed networking cards, and eight 3.5-inch SATA/NVMe U.2 hot-swap, tool-less drive bays. The platform supports up to four double-width GPU cards that can be easily scaled out to improve HPC and deep learning performance.
The Transport HX TS75A-B8252 is a 2U dual-socket server platform optimized for virtualization applications with support for 32 DDR4-3200/2933 DIMM slots and up to nine PCIe 4.0 x8 slots. The TS75A-B8252 accommodates 26 2.5-inch SATA hot-swap, tool-less drive bays with up to eight NVMe U.2 support by configuration. The Transport HX FT65T-B8030 is a 4U convertible tower server platform designed for cost-effective HPC applications. The system supports a single AMD EPYC 7003 Series processor, eight DDR4-3200 DIMM slots, eight 3.5-inch SATA, and two NVMe U.2 hot-swap, tool-less drive bays. The FT65T-B8030 supports four double-width PCIe 4.0 x16 slots for GPUs to accelerate HPC applications.
Transport CX lineup is designed for cloud and data analytics requiring large memory capacity
The Transport CX GC79-B8252 and Transport CX GC79A-B8252 are 1U dual-socket server platforms that are ideal for high-density data center deployment for a variety of memory-based computing applications. Both systems feature 32 DDR4-3200/2933 DIMM slots, two standard PCIe 4.0 x16 expansion slots, and an OCP 3.0 LAN mezzanine slot. The GC79-B8252 platform provides four 3.5-inch SATA and four 2.5-inch NVMe U.2 hot-swap, tool-less drive bays, while the GC79A-B8252 platform offers twelve 2.5-inch drive bays with up to twelve NVMe U.2 support.
The Transport CX GC68-B8036-LE and Transport CX GC68A-B8036 are cost-optimized single-socket cache server platforms featuring 16 DDR4-3200/2933 DIMMs, a pair of PCIe 4.0 x16 expansion slots and an OCP 2.0 LAN mezzanine slot in a 1U chassis. The GC68-B8036-LE accommodates four 3.5-inch SATA hot-swap, tool-less drive bays for large storage capacity and four 2.5-inch hot-swap, tool-less NVMe U.2 bays for application cache usage; the GC68A-B8036 offers twelve 2.5-inch hot-swap, tool-less drive bays with support for up to twelve NVMe U.2 devices for applications for high storage performance requirements.
The Transport CX TN73-B8037-X4S is a 2U multi-node server platform with four front-serviced compute nodes. Each node supports one AMD EPYC 7003 Series processor, four 2.5-inch hot-swap, tool-less NVMe/SATA drive bays, eight DDR4-3200 DIMM slots, three internal cooling fans, two standard PCIe 4.0 x16 expansion slots, two internal NVMe M.2 slots and one OCP 2.0 LAN mezzanine slot. The platform is suited for high-density data center deployments and targets scale-out applications with large numbers of nodes.
Transport SX lineup to deliver massive I/O and memory bandwidth for storage applications
The Transport SX TS65-B8253 is a 2U dual-socket hybrid software storage server for various datacenter and enterprise deployments supporting 16 DDR4-3200 DIMM slots and seven standard PCIe 4.0 slots. The platform offers twelve front 3.5-inch hot-swap, tool-less SATA drive bays with support for up to four U.2 NVMe SSDs, and two rear 2.5-inch hot-swap, tool-less SATA drive bays for boot drive deployment.
TYAN’s Transport SX TS65-S8036 and Transport SX TS65A-S8036 are 2U single-socket storage servers with support for 16 DDR4-3200/2933 DIMM slots, five PCIe 4.0 and one OCP 2.0 LAN mezzanine slots. The TS65-S8036 accommodates twelve front 3.5-inch and two rear 2.5-inch hot-swap, tool-less SATA drive bays for cloud storage applications, up to four NVMe U.2 devices are supported on the front twelve drive bays; the TS65A-S8036 offers 26 front and two rear 2.5-inch hot-swap, tool-less drive bays for high-performance data streaming applications, the 26 front drive bays can support up to 24 NVMe U.2 devices by configuration.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210602005045/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom